Cellebrite DI (NASDAQ:CLBT) CMO David Nicholas Gee Sells 4,323 Shares

Cellebrite DI Ltd. (NASDAQ:CLBT) CMO David Nicholas Gee sold 4,323 shares of the company’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $11.36, for a total transaction of $49,109.28. Following the completion of the transaction, the chief marketing officer directly owned 135,281 shares of the company’s stock, valued at approximately $1,536,792.16. The trade was a 3.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Nicholas Gee also recently made the following trade(s):

• On Friday, August 21st, David Nicholas Gee sold 2,198 shares of Cellebrite DI stock. The shares were sold at an average price of $11.24, for a total value of $24,705.52.
• On Wednesday, August 12th, David Nicholas Gee sold 230 shares of Cellebrite DI stock. The shares were sold at an average price of $16.07, for a total value of $3,696.10.

Cellebrite DI Trading Down 1.7%

Shares of CLBT stock traded down $0.20 on Tuesday, hitting $11.29. 2,235,695 shares of the stock were exchanged, compared to its average volume of 2,270,624. The firm has a market capitalization of $2.82 billion, a P/E ratio of 51.32, a price-to-earnings-growth ratio of 1.53 and a beta of 1.18. Cellebrite DI Ltd. has a fifty-two week low of $9.58 and a fifty-two week high of $19.98. The business has a 50-day moving average of $14.24 and a 200 day moving average of $13.83.

Institutional Investors Weigh In On Cellebrite DI

Several large investors have recently made changes to their positions in the stock. Towarzystwo Funduszy Inwestycyjnych PZU SA raised its position in Cellebrite DI by 81.0% during the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after acquiring an additional 850 shares in the last quarter. Advisory Services Network LLC bought a new position in shares of Cellebrite DI in the 3rd quarter valued at about $40,000. CWM LLC increased its stake in shares of Cellebrite DI by 57.0% during the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after purchasing an additional 889 shares during the last quarter. Elevation Wealth Partners LLC bought a new stake in shares of Cellebrite DI in the 2nd quarter valued at about $44,000. Finally, Vestcor Inc acquired a new stake in Cellebrite DI in the 3rd quarter valued at about $70,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Wall Street Analyst Weigh In

CLBT has been the subject of several research reports. JPMorgan Chase & Co. decreased their price target on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday, August 14th. Needham & Company LLC decreased their target price on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research report on Friday, August 14th. Lake Street Capital lowered their price target on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. DA Davidson cut their price target on shares of Cellebrite DI from $22.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Finally, Weiss Ratings downgraded shares of Cellebrite DI from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, August 13th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.70.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.